Ellis C N, Swanson N A, Grekin R C, Goldstein N G, Bassett D R, Anderson T F, Voorhees J J
Arch Dermatol. 1982 Aug;118(8):559-62.
We investigated changes in serum triglyceride, cholesterol, and high-density lipoprotein cholesterol (HDLC) levels during etretinate administration in 21 patients with psoriasis. Mean serum triglyceride and cholesterol values showed a statistically significant increase during etretinate therapy compared with placebo treatment; mean HDLC levels did not change. During etretinate therapy, elevations out of the normal range occurred in 77% of the patients for serum triglycerides and 25% for serum cholesterol. Eight weeks after discontinuation of the drug regimen, patients' mean serum triglyceride and cholesterol levels were not statistically different from those found prior to therapy. Nevertheless, eight weeks after therapy had been stopped, six (32%) of 19 patients had cholesterol values that were still 20% or more above their baseline levels; the prolonged etretinate excretion time could have been responsible. The mechanisms for the etretinate-induced lipid elevations are unknown.
我们对21例银屑病患者服用依曲替酯期间的血清甘油三酯、胆固醇和高密度脂蛋白胆固醇（HDLC）水平变化进行了研究。与安慰剂治疗相比，依曲替酯治疗期间血清甘油三酯和胆固醇的平均水平出现了具有统计学意义的升高；平均HDLC水平未发生变化。在依曲替酯治疗期间，77%的患者血清甘油三酯和25%的患者血清胆固醇出现超出正常范围的升高。停药方案停用8周后，患者血清甘油三酯和胆固醇的平均水平与治疗前相比无统计学差异。然而，治疗停止8周后，19例患者中有6例（32%）的胆固醇值仍比其基线水平高出20%或更多；依曲替酯排泄时间延长可能是原因所在。依曲替酯诱导血脂升高的机制尚不清楚。
